TORNTPHARM

** Shares of Torrent Pharmaceuticals TORP.NS rise as much as 3.5% to 3,360.70 rupees

** The pharmaceutical company on Friday reported a 13.5% Y/Y rise in Q3 consol net profit while total rev from ops rose 2.8% Y/Y

** TORP is the only stock in green in the Nifty pharma sub-index .NIPHARM, which is down 2.3%

** Stock currently above 50-day, 100-day and 200-day exponential moving averages

** More than 783,000 shares change hands, 3.1x of 30-day avg

** Avg rating of 26 analysts equivalent of "hold", median PT is 3,584.50 rupees - LSEG data

** Stock rose 45.7% in 2024 vs 39.1% gains by Nifty pharma

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Jan 24 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:

• DIVIDEND 26 RUPEES PER SHARE

• Q3 CONSOL NET PROFIT 5.03 BILLION RUPEES; IBES EST 5.13 BILLION RUPEES

• Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 28.09 BILLION RUPEES; IBES EST 29.92 BILLION RUPEES

Source text: [ID:]

Further company coverage: TORP.NS

(([email protected];;))

Dec 26 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:

• ISSUES COMMERCIAL PAPERS WORTH 2 BILLION RUPEES

Source text: ID:nBSE2DtznC

Further company coverage: TORP.NS

(([email protected];))

** Shares of drugmaker Torrent Pharma TORP.NS climb 3% to 3,455 rupees in early trade

** Co says it will acquire three diabetes treatment brands - Cospiaq, Cospiaq Met and Xilingio - from German biopharmaceuticals firm Boehringer Ingelheim

** Acquisition to be completed in March 2025

** TORP, which makes diseases for long-time illnesses like diabetes and thyroid, has been marketing these brands since 2022 under a co-marketing agreement with Boehringer

** Analysts rate TORP, rivals Mankind Pharma MNKI.NS and Glenmark Pharma GLEN.NS at "buy" - LSEG data

** TORP's ~50% YTD gain smaller than GLEN's 81% climb but bigger than MNKI's 31% rise

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Dec 4 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:

• ENTERS INTO AGREEMENT WITH BOEHRINGER INGELHEIM TO ACQUIRE 3 ANTI-DIABETES BRANDS

• ACQUISITION EXPECTED TO COMPLETE IN MARCH 2025

Source text: ID:nBSEbDW2f4

Further company coverage: TORP.NS

(([email protected];))

** Shares of Torrent Pharmaceuticals Ltd TORP.NS rise as much as 2.7% to 3,184.75 rupees

** The pharma co says United States Food and Drug Administration (USFDA) has issued establishment inspection report with voluntary action indicated classification for Pithampur manufacturing facility

** Adds that inspection has been successfully closed by the FDA

** Stock on track to snap five weeks of losses

** Mean rating of 27 brokerages rating the stock is "buy"; their median PT is 3,589 rupees - LSEG data

** TORP stock has climbed 2.2% so far this week, adding to YTD gains of 37.8%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

** Shares of Torrent Pharmaceuticals TORP.NS fall as much as 4.1% to 3,084.80 rupees, lowest since July 25

** More than 449,000 shares change hands in nine block deals at 3,094.40-3,125.25 rupees each -LSEG data

** Prices at a discount to stock's last close of 3,215.65 rupees

** Broadcaster ET Now on Tuesday reported TORP promoters to sell 2.9% stake via block deals

** Stock among top losers in Nifty pharma index .NIPHARM which is down 1.3%

** Over 2 mln shares traded, 6x of 30-day avg and most active session since Sept 2023

** Stock up 36% YTD vs 33% gain in pharma index

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Oct 29 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:

• TORRENT PHARMA PROMOTER TO SELL UPTO 2.9% STAKE VIA BLOCK DEALS ON OCT 30 - ET NOW

Source text: [ID:]

Further company coverage: TORP.NS

(([email protected];;))

** Shares of Torrent Pharmaceuticals TORP.NS fall 2.4% to 3,350 rupees

** The pharmaceuticals company's Q2 consol net profit and revenue missed analysts' estimates, per data compiled by LSEG

** Smaller-than-expected profit due to shutdown of an insulin manufacturing facility

** Q2 consol net profit up 17.4% Y/Y, rev rises 8.6% Y/Y

** Trading vols at 384,205, 1.3X the 30-day average

** TORP up ~45% YTD

(Reporting by Vijay Malkar)

(([email protected];))

Oct 25 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:

• Q2 CONSOL NET PROFIT 4.53 BILLION RUPEES; IBES EST 4.97 BILLION RUPEES

• Q2 CONSOL TOTAL REVENUE FROM OPERATIONS 28.89 BILLION RUPEES; IBES EST 29.78 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: TORP.NS

(([email protected];;))

Sept 26 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:

• INCORPORATED UNIT NAMELY TORRENT PHARMACEUTICALS CHILE SPA

Source text for Eikon: ID:nBSE7djQ49

Further company coverage: TORP.NS

(([email protected];;))

Sept 20 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:

• USFDA CONDUCTED ROUTINE GMP INSPECTION OF FORMULATION MANUFACTURING FACILITY

• END OF INSPECTION, AGENCY ISSUED FORM FDA 483 WITH ONE OBSERVATION

• FORM FDA 483 WITH ONE OBSERVATION IS PROCEDURAL IN NATURE

Source text for Eikon: ID:nBSE9Dt3XX

Further company coverage: TORP.NS

(([email protected];;))

Torrent Pharmaceuticals Ltd TORP.NS:

• TORRENT PHARMA- USFDA HAS ISSUED ESTABLISHMENT INSPECTION REPORT FOR INDRAD, GUJARAT FACILITY

• TORRENT PHARMA - INSPECTION CONDUCTED BY USFDA FOR MANUFACTURING FACILITY AT INDRAD

• TORRENT PHARMA- INSPECTION HAS NOW BEEN SUCCESSFULLY CLOSED BY USFDA

• TORRENT PHARMA - USFDA ISSUED ESTABLISHMENT INSPECTION REPORT WITH VOLUNTARY ACTION INDICATED

Source text for Eikon: ID:nBSE6yKYHr

Further company coverage: TORP.NS

-- Source link: https://bit.ly/4fLAmu7

-- Note: Reuters has not verified this story and does not vouch for its accuracy

((Bengaluru newsroom, [email protected]))

** Shares of Torrent Pharmaceuticals TORP.NS down 2.9% to 3,046.5 rupees

** Stock is the biggest loser on Nifty Pharma index .NIPHARM, which is up 0.55%

** Drug maker's Q1 profit rose less than expected

** TORP among nine "buy"-rated stocks on 20-member pharma index -LSEG data

** TORP up ~32% YTD vs ~24% climb in pharma index

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

By VarunVyas Hebbalalu and Kashish Tandon

BENGALURU, July 5 (Reuters) - India's Emcure Pharmaceuticals EMCU.NS drew strong interest for its $234 million initial public offering (IPO) as investors bet on its slate of women's healthcare and HIV treatments to drive growth in a high-margin market.

The Bain Capital-backed company's IPO was fully subscribed on the first day of bidding and over the three-day process, it got bids worth up to 937.11 billion rupees ($11.23 billion), nearly 68 times the amount on offer, exchange data showed.

Bain sold nearly a third of its 13.07% stake in Emcure, with existing investors overall selling shares worth 11.52 billion rupees.

Emcure raised 8 billion rupees by issuing new shares in the IPO, which valued the company at up to 190.60 billion rupees, per Reuters calculations.

Emcure is going public in India's red-hot IPO market where more than 100 companies have raised around $4.6 billion through IPOs so far this year, more than double the same period last year, as per LSEG data.

Analysts are betting on its focus on areas such as gynaecology, where it has a market-leading 14% share, and HIV treatments. The generics market is dominated by firms such as Sun Pharma SUN.NS, Mankind Pharma MNKI.NS, Torrent Pharma TORP.NS and Abbott India ABOT.NS.

Institutional buyers, including foreign investors, banks and mutual funds, bid for 196 times the shares on offer, while retail investors bid for seven times their reserved shares.

Anchor investors, including Goldman Sachs and Abu Dhabi Investment Authority (ADIA), had earlier bought shares worth a total of 5.83 billion rupees.

Emcure's expansion-related spending has hit earnings over the last two years but the ramp-up of facilities will boost sales in the near term, said Sneha Poddar, vice president of research at Motilal Oswal Financial Services.

The stock's price-to-earnings ratio of 36.6 is also attractive compared to the industry average of 40.4, and can help it "pop" in its trading debut, analysts said.

($1 = 83.4690 Indian rupees)

(Reporting by Kashish Tandon and Varun Hebbalalu in Bengaluru; Editing by Savio D'Souza)

(([email protected]; 8800437922;))

BENGALURU, June 21 (Reuters) - Japan's Takeda Pharmaceutical 4502.T gave India's Sun Pharmaceutical SUN.NS and Cipla CIPL.NS the rights to commercialize gastrointestinal drug Vonoprazan in the country.

The drug, which is sold in the form of tablets under the brand name 'Voltapraz', blocks a key step in the production of stomach acid, Sun Pharma said on Friday. Cipla announced the agreement late on Thursday.

Takeda has granted both drugmakers non-exclusive patent licensing rights for the drug.

Gastroesophageal reflux disease (GERD) affects 5% to 28.5% of India's population.

Earlier this month, Torrent Pharmaceuticals TORP.NS also partnered with Takeda to commercialize Vonoprazan in India.

Sun Pharmaceutical's shares rose 0.7% on Friday, while Cipla was up 1%.

(Reporting by Navamya Ganesh Acharya in Bengaluru; Editing by Sonia Cheema)

(([email protected]; +91 8805175330 ;))

** Shares of Torrent Pharmaceuticals TORP.NS rise as much as 3.1% to hit record high of 2,866.75 rupees

** Co scales record high-level for second straight session

** Pharmaceutical co on Wednesday right before market-close said it entered into non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialise its Novel Gastrointestinal drug in India

** Stock up 2.3% after the announcement

** Avg rating of 27 analysts is equivalent of "buy", median PT is 2,900 rupees - LSEG data

** Stock rose 12.8% in March quarter, its fourth straight quarterly gains

** Stock up 23.4% YTD

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

June 5 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:

• ENTERS INTO NON-EXCLUSIVE PATENT LICENSING AGREEMENT WITH TAKEDA PHARMACEUTICALS

• AGREEMENT TO COMMERCIALIZE NOVEL GASTROINTESTINAL DRUG IN INDIA

Source text for Eikon: ID:nBSEC69XN

Further company coverage: TORP.NS

(([email protected];;))

** Shares of Torrent Pharmaceuticals TORP.NS rise as much as 7%, last up 2.8% to 2,686.75 rupees

** Drugmaker's Q4 profit up 56.5% YoY and roughly meets estimates

** More than 706,000 shares traded so far logging second-busiest day this year; busiest day was May 3

** Peer Mankind Pharma's MNKI.NS Q4 profit also up

** TORP and MNKI each rated "buy" on avg - LSEG data

** TORP and MNKI up ~16% and ~6% YTD

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

May 24 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:

• TORRENT PHARMACEUTICALS Q4 CONSOL NET PROFIT 4.49 BILLION RUPEES; LSEG IBES EST 4.51 BILLION RUPEES

• TORRENT PHARMACEUTICALS Q4 CONSOL NET REVENUE FROM OPERATIONS 27.45 BILLION RUPEES

• TORRENT PHARMACEUTICALS YEAR AGO Q4 CONSOL NET PROFIT 2.87 BILLION RUPEES, REVENUE 24.91 BILLION RUPEES

• TORRENT PHARMACEUTICALS - FINAL DIVIDEND OF 6 RUPEES/SHR

• TORRENT PHARMACEUTICALS - RECOMMENDED TO MEMBERS TO OBTAIN APPROVAL FOR ISSUANCE OF EQUITY SHARES INCLUDING CONVERTIBLE BONDS / DEBENTURES

Further company coverage: TORP.NS

(([email protected];))

BENGALURU, May 14 (Reuters) - Cipla's CIPL.NS promoter group is looking to sell a 2.53% stake in India's third-largest drugmaker via a block deal worth 26.37 billion rupees (nearly $316 million), CNBC-TV18 reported on Tuesday, citing sources.

The promoter group will sell its stake in Cipla at a per-share price range of 1,289.5 rupees to 1,357.35 rupees, the report said.

The price range of the proposed stake sale means it will be sold at no more than the value of the stock's last closing price, which was 4% lower, at 1,357.35 rupees.

Cipla did not immediately respond to a Reuters request for comment.

The company, with a market capitalisation of over $13 billion, is known for making the anti-allergy drug Cetirizine.

Local news media first reported in July 2023 that Cipla's top shareholders were in talks to sell a part of their stake in the company to private equity funds such as Blackstone BX.N and Baring Asia.

India's Torrent Pharmaceuticals TORP.NS was in talks with Apollo Global Management APO.N to borrow up to $1 billion for a bid to buy a stake in Cipla, Reuters reported last September.

The stake sale plan faced hurdles at the time as the promoters were not in agreement about the common valuation, ET Now had reported.

($1 = 83.4660 Indian rupees)

(Reporting by Manvi Pant and Ashna Teresa Britto in Bengaluru; Editing by Pooja Desai)

(([email protected]; +918447554364;))

May 2 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:

• GOT MULTIPLE ORDERS FROM TAX AUTHORITIES

Source text for Eikon: ID:nBSE8S7Z3b

Further company coverage: TORP.NS

(([email protected];))

- Source link: (https://bityl.co/P5hQ)

- Note: Reuters has not verified this story and does not vouch for its accuracy

(Bengaluru newsroom)

(([email protected]; +91 80 6749 1310;))

** Shares of Indian drugmaker Torrent Pharmaceuticals TORP.NS jump 3% to a record 2,742.60 rupees

** Stock currently up 1.1%

** Co said the U.S. Food and Drug Administration (FDA) has closed inspection at its Gujarat facility and issued an establishment inspection report

** Average rating of 25 analysts covering the stock is "buy," median TP 2,695 rupees - LSEG data

** Stock up ~17% YTD after an ~49% jump in 2023

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

** Shares of Torrent Pharma rise ~6% to all-time high of 2,670.65 rupees; top gainer on pharma index .NIPHARM which is up ~2%

** Indian drugmaker reports 30% rise in pre-tax profit on strong demand

** Stock has gained 6.3% in last two sessions

** Kotak analysts expect steady pace of launches and price hikes to drive ~14% sales CAGR in Brazil, second-biggest rev generator for TORP

** India business, TORP's biggest, to grow at ~13% CAGR over 2-year period on ~5% price hikes, OTC foray and ~8% volume growth - Antique Stock Broking

** U.S business to see improvement from Q1FY25 on new product launches - Nuvama

** Avg rating on TORP, larger rivals Cipla CIPL.NS and Sun Pharma SUN.NS at "buy" - LSEG

** TORP rose ~49% in 2023, vs pharma index's ~34% climb

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Feb 2 (Reuters) - Torrent Pharmaceuticals Ltd TORP.NS:

• Q3 CONSOL NET PROFIT 4.43 BILLION RUPEES; LSEG IBES EST 4.24 BILLION RUPEES

• Q3 CONSOL NET REVENUE FROM OPERATIONS 27.32 BILLION RUPEES

• DIVIDEND 22 RUPEES PER SHARE

• YEAR AGO Q3 CONSOL NET PROFIT 2.92 BILLION RUPEES, REVENUE 24.91 BILLION RUPEES

Further company coverage: TORP.NS

(([email protected];))

** Shares of drugmaker Torrent Pharmaceuticals TORP.NS rise as much as 2.4% to 2,275 rupees to hit a new record high

** Stock has hit record high in each of the last five sessions, including on Tuesday

** On Friday, local TV channel ET Now reported citing sources that TORP has scraped non-binding bid for buyout of founders' stake in drugmaker Cipla CIPL.NS

** Stock among top gainers in Nifty pharma index .NIPHARM, which is up 1.01%

** More than 160,000 shares traded by 12:29 p.m. IST, 0.6x of 30-day avg

** Avg rating of 27 analysts equivalent to "buy" rating, median PT is 2,167.50 rupees - LSEG data

** Stock up 46.4% YTD vs Nifty pharma, which is up 31.4%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Dec 22 (Reuters) -

• TORRENT PHARMA WITHDRAWS NON-BINDING BID FOR BUYOUT OF FOUNDERS STAKE IN CIPLA STATING LACK OF CONSENSUS OVER VALUATION - ET NOW

Further company coverage: CIPL.NS

(([email protected];))

** Torrent Pharmaceuticals TORP.NS shares fall as much as 2.2% to 2,032 rupees, lowest since Nov. 17

** US FDA issued a Form 483 to the co, with 5 procedural observations, following its Pre-Approval Inspection at the co's facility in Gujarat

** Avg rating of 27 analysts covering the stock is "buy;" their median PT is 2,167.5 rupees - LSEG

** Session's loss trims YTD gains to 32%; stock lost ~5 last year

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))